Ubs Group Ag Geron Corp Transaction History

Ubs Group Ag

$555 Billion
Q2 2025

A detailed history of Ubs Group Ag transactions in Geron Corp stock. As of the latest transaction made, Ubs Group Ag holds 11,745,012 shares of GERN stock, worth $15.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,745,012

Previous 5,211,433 125.37%

Holding current value

$15.9 Million

Previous $8.29 Million 99.86%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.18 - $1.62 $7.71 Million - $10.6 Million	6,533,579 Added 125.37%	11,745,012 $16.6 Million
Q1 2025 May 13, 2025	SELL	$1.59 - $3.6 $2.25 Million - $5.09 Million	-1,412,806 Reduced 21.33%	5,211,433 $8.29 Million
Q4 2024 Feb 14, 2025	BUY	$3.3 - $4.44 $11.2 Million - $15.1 Million	3,401,763 Added 105.56%	6,624,239 $23.4 Million
Q3 2024 Nov 14, 2024	BUY	$4.17 - $4.99 $3.77 Million - $4.52 Million	905,115 Added 39.06%	3,222,476 $14.6 Million
Q2 2024 Aug 13, 2024	BUY	$3.1 - $5.09 $1.58 Million - $2.6 Million	510,050 Added 28.22%	2,317,361 $9.83 Million
Q1 2024 May 13, 2024	BUY	$1.75 - $3.44 $639,989 - $1.26 Million	365,708 Added 25.37%	1,807,311 $5.96 Million
Q4 2023 Feb 09, 2024	BUY	$1.74 - $2.31 $1.38 Million - $1.83 Million	790,423 Added 121.38%	1,441,603 $3.04 Million
Q3 2023 Nov 09, 2023	SELL	$2.11 - $3.28 $2,983 - $4,637	-1,414 Reduced 0.22%	651,180 $1.38 Million
Q2 2023 Aug 11, 2023	SELL	$1.97 - $3.69 $273,110 - $511,563	-138,635 Reduced 17.52%	652,594 $2.09 Million
Q1 2023 May 12, 2023	BUY	$2.14 - $3.4 $368,629 - $585,673	172,257 Added 27.83%	791,229 $1.72 Million
Q4 2022 Feb 08, 2023	BUY	$2.03 - $2.42 $1.13 Million - $1.34 Million	555,583 Added 876.47%	618,972 $1.5 Million
Q3 2022 Nov 10, 2022	SELL	$1.67 - $2.94 $113,743 - $200,243	-68,110 Reduced 51.8%	63,389 $149,000
Q2 2022 Aug 10, 2022	SELL	$1.19 - $1.65 $576,597 - $799,484	-484,536 Reduced 78.65%	131,499 $203,000
Q1 2022 May 16, 2022	BUY	$0.99 - $1.6 $12,175 - $19,676	12,298 Added 2.04%	616,035 $838,000
Q4 2021 Feb 14, 2022	BUY	$1.22 - $1.72 $233,821 - $329,650	191,657 Added 46.51%	603,737 $737,000
Q3 2021 Nov 15, 2021	BUY	$1.2 - $1.5 $438,690 - $548,362	365,575 Added 786.1%	412,080 $564,000
Q2 2021 Aug 13, 2021	SELL	$1.25 - $1.83 $456,363 - $668,116	-365,091 Reduced 88.7%	46,505 $65,000
Q1 2021 May 12, 2021	BUY	$1.52 - $2.1 $616,249 - $851,396	405,427 Added 6572.01%	411,596 $650,000
Q3 2020 Nov 12, 2020	SELL	$1.59 - $2.19 $59,566 - $82,043	-37,463 Reduced 85.86%	6,169 $11,000
Q2 2020 Jul 31, 2020	SELL	$1.05 - $2.18 $72,094 - $149,680	-68,661 Reduced 61.14%	43,632 $95,000
Q1 2020 May 01, 2020	SELL	$0.89 - $1.49 $114,443 - $191,596	-128,588 Reduced 53.38%	112,293 $133,000
Q4 2019 Feb 14, 2020	BUY	$1.27 - $1.54 $158,555 - $192,264	124,847 Added 107.6%	240,881 $327,000
Q3 2019 Nov 14, 2019	BUY	$1.15 - $1.59 $119,721 - $165,528	104,106 Added 872.79%	116,034 $154,000
Q2 2019 Aug 14, 2019	SELL	$1.37 - $2.02 $34,667 - $51,116	-25,305 Reduced 67.96%	11,928 $17,000
Q1 2019 May 14, 2019	SELL	$1.01 - $1.83 $8,314 - $15,064	-8,232 Reduced 18.11%	37,233 $62,000
Q4 2018 Feb 14, 2019	BUY	$0.98 - $1.85 $4,976 - $9,394	5,078 Added 12.57%	45,465 $45,000
Q3 2018 Nov 14, 2018	SELL	$1.76 - $6.38 $5,037 - $18,259	-2,862 Reduced 6.62%	40,387 $71,000
Q2 2018 Aug 14, 2018	SELL	$3.29 - $4.82 $305,029 - $446,881	-92,714 Reduced 68.19%	43,249 $148,000
Q1 2018 May 15, 2018	BUY	$1.81 - $5.98 $172,188 - $568,889	95,132 Added 232.99%	135,963 $578,000
Q4 2017 Feb 14, 2018	SELL	$1.8 - $2.32 $87,811 - $113,178	-48,784 Reduced 54.44%	40,831 $74,000
Q3 2017 Nov 14, 2017	BUY	$1.99 - $2.65 $81,884 - $109,042	41,148 Added 84.9%	89,615 $195,000
Q2 2017 Aug 14, 2017	SELL	N/A	-3,554 Reduced 6.83%	48,467 $135,000
Q1 2017 Nov 14, 2017	BUY	N/A	52,021	52,021 $118,000

Others Institutions Holding GERN

# of Institutions

281

Shares Held

509M

Call Options Held

884K

Put Options Held

564K

View Full List

About GERON CORP

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $510M
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

More about GERN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account